Exocrine Pancreatic Function Testing in Cystic Fibrosis

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2016 by Haukeland University Hospital
University of Bergen
Information provided by (Responsible Party):
Haukeland University Hospital
ClinicalTrials.gov Identifier:
First received: October 4, 2011
Last updated: January 21, 2016
Last verified: January 2016

Purpose The purpose of this study is to develop and validate multimodal testing of exocrine pancreatic function (EPF). The investigators will be testing exocrine pancreatic function in patients with cystic fibrosis (CF). Exocrine pancreatic function and imaging will be correlated to age group, genotype, nutritional status and quality of life. Earlier detection of exocrine pancreatic failure in the non classical form of cystic fibrosis may be of therapeutically benefit.

Hypotheses Endoscopic short test can be applied in diagnosing and monitoring exocrine pancreatic function in patients with cystic fibrosis.

New functional testing of exocrine pancreatic function is superior to traditional testing with fecal elastase.

MRI and ultrasound methods can give volume output estimate in cystic fibrosis patients.

Contrast enhanced ultrasound can quantify reduced or delayed pancreatic perfusion and parenchymal changes in cystic fibrosis patients.

Elastography/ CEUS can be used in prediction and monitoring of fibrosis development and development of hepatocellular carcinoma in the liver of cystic fibrosis patients.

Immunohistochemical quantification of secretin/ cholecystokinin (CCK) producing cell in duodenum can be utilized as a model hormonal signaling in cystic fibrosis patients with exocrine pancreatic function.

Cystic Fibrosis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Pancreatic Failure in Patients With Cystic Fibrosis A Multimodal Study of Exocrine Pancreatic Failure in Cystic Fibrosis

Resource links provided by NLM:

Further study details as provided by Haukeland University Hospital:

Primary Outcome Measures:
  • peak lipase IE [ Time Frame: one year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • enzyme production [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • emzyme production [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
Duodenal juice Serum, full Blood Saliva

Estimated Enrollment: 60
Study Start Date: January 2011
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Cystic fibrosis patients
Consecutive cystic fibrosis patients attending regular Controls at the CF clinic in Bergen
Healthy controls
Age and gender matchet healthy Controls recruited by Board notice and advertising.

Detailed Description:

Study design: Observational, cohort studies.

Patient characterization: Age, gender, and Genetic status from electronical records.

Exocrine function testing (EPF): Secretin stimulated ultrasound and short endoscopic secretin test (EST). Faecal Elastase.

Imaging: Transabdominal ultrasound of the liver and pancreas. secretin stimulated MRI. Contrast enhanced ultrasound (CEUS) of the pancreas using SonoVue contrast.


Study 1: Exocrine pancreatic function by duodenal bicarbonate/ Enzymes related to Genetics and F elastase.

Study 2: Ultrasound parenchymal changes of the pancreas related to Genetics and EPF.

Study 3/4: Pancreatic secretion by ultrasound, MRI and EST related to EPF Study 5; Perfusion of the pancreas by CEUS related to EPF

Study 6: Genotype-phenotype conciderations of the CF pancreas.


Ages Eligible for Study:   15 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Cystic fibrosis patients over the age of 15 years Healthy controls between 18 and 67 years

Inclusion Criteria:

  • Diagnosis cystic fibrosis. Age over 15 years. Assigned to routine control at department of lung diseases, Haukeland university hospital.

Exclusion Criteria:

  • Unable to concent, allergies to Sonovue ultrasound contrast, pregnant or breastfeeding, contraindications against endoscopy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01446861

Contact: Georg Dimcevski, MD, PhD 55972903 georg.dimcevski@helse-bergen.no
Contact: Trond Engjom, MD 55975000 trond.engjom@heløse-bergen.no

Haukeland University Hospital Recruiting
Bergen, Norway, 5020
Contact: Georg Dimcevski, MD, PhD    55972903    georg.dimcevski@helse-bergen.no   
Principal Investigator: Georg Dimcevski, Md, PhD         
Sponsors and Collaborators
Haukeland University Hospital
University of Bergen
Principal Investigator: Georg Dimcevski, MD, PhD Haukeland University Hospital
Study Director: Odd H Gilja, Professor Haukeland University Hospital
  More Information

Responsible Party: Haukeland University Hospital
ClinicalTrials.gov Identifier: NCT01446861     History of Changes
Other Study ID Numbers: 2010/2857-7 
Study First Received: October 4, 2011
Last Updated: January 21, 2016
Health Authority: Norway:National Committee for Medical and Health Research Ethics

Keywords provided by Haukeland University Hospital:
Cystic fibrosis
Exocrine function
Contrast ultrasound

Additional relevant MeSH terms:
Cystic Fibrosis
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 24, 2016